Evaluating the Association Between Pericardial Fat and Coronary Heart Disease - Ancillary to MESA

This study has been completed.
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Jingzhong Ding, PhD, Wake Forest University
ClinicalTrials.gov Identifier:
First received: November 22, 2006
Last updated: January 15, 2013
Last verified: January 2013
Coronary heart disease (CHD) is the leading cause of death in the United States. One common risk factor for CHD is obesity. The presence of certain types of fat over others is more commonly associated with the development of CHD. This study will use data from a previous study to examine the association between pericardial fat, a type of fat that surrounds the heart, and CHD.

Coronary Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Pericardial Fat and Subclinical and Clinical Measures of Coronary Heart Disease - Ancillary to MESA

Resource links provided by NLM:

Further study details as provided by Wake Forest School of Medicine:

Primary Outcome Measures:
  • Coronary heart disease events [ Time Frame: 6 years ] [ Designated as safety issue: No ]

Enrollment: 6814
Study Start Date: August 2006
Study Completion Date: May 2012
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Detailed Description:

CHD is caused by a narrowing of the small blood vessels that supply blood and oxygen to the heart. It usually results from atherosclerosis, a condition in which deposits of fat, cholesterol, and other substances build up along the inner walls of arteries. Risk factors for CHD include tobacco use, high blood pressure, diabetes, and obesity. Visceral fat, the type of fat found in the abdomen and surrounding vital organs, is considered a greater risk factor for CHD than subcutaneous fat, the type of fat found directly below the skin. Pericardial fat, the fat surrounding the heart, is similar to visceral fat, and may be particularly damaging because of its lipotoxicity effects and its ability to trigger inflammation in the coronary arteries. Increased amounts of pericardial fat may therefore accelerate the development of atherosclerosis and CHD. The purpose of this study is to evaluate the relationship between pericardial fat and the development of CHD.

This study will use previously collected data from participants in the Multi-Ethnic Study of Atherosclerosis (MESA) study, a study that examined characteristics of the subclinical, or the early stages of, cardiovascular disease in individuals. There will be no study visits specifically for this study. Participants' study data and computed tomography (CT) scans will be analyzed to determine the following: 1) the presence of pericardial fat and subclinical CHD at study entry; 2) changes in pericardial fat levels and plaque formation; and 3) the presence of pericardial fat and CHD at a 6-year follow-up visit.


Ages Eligible for Study:   45 Years to 84 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Participant in the MESA study

Inclusion Criteria:

  • Participant in the MESA study
  • Had a baseline and 6-year follow-up CT scan as part of the MESA study

Exclusion Criteria:

  • Participant did not have a baseline or 6 year follow-up CT in the MESA study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00402922

Sponsors and Collaborators
Wake Forest University
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Jingzhong Ding, MD, PhD Wake Forest School of Medicine
  More Information

No publications provided

Responsible Party: Jingzhong Ding, PhD, Associate Professor, Wake Forest University
ClinicalTrials.gov Identifier: NCT00402922     History of Changes
Other Study ID Numbers: 1358  R01HL085323-01 
Study First Received: November 22, 2006
Last Updated: January 15, 2013
Health Authority: United States: Federal Government

Keywords provided by Wake Forest School of Medicine:
Coronary Heart Disease

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Heart Diseases
Myocardial Ischemia
Arterial Occlusive Diseases
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on February 04, 2016